Filtros de búsqueda

Lista de obras de

Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience.

artículo científico publicado en 2011

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.

artículo científico publicado en 2017

Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

artículo científico publicado en 2013

Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study

artículo científico publicado en 2020

Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial

artículo científico publicado en 2020

Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease

artículo científico publicado en 2020

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

artículo científico publicado en 2017

Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.

artículo científico publicado en 2015

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.

artículo científico publicado en 2017

Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study

artículo científico publicado en 2015

Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials

artículo científico

Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial

artículo científico publicado en 2019

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study

artículo científico publicado en 2017

Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study

scientific article published on 30 August 2013

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda